Brainsway Ltd. Sponsored ADR
BWAY Healthcare Medical Devices
Brainsway Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $52.2 million, up 27.3% from fiscal 2024. In the quarter to June 2026, revenue grew 35.4%, EPS grew 40.0% and free cash flow fell 51.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow BWAY
Brainsway Ltd. Sponsored ADR (BWAY) EV/Sales
As of 16 October 2026, Brainsway Ltd. Sponsored ADR (BWAY) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from −1.3× (June 2024) to 6.4× (December 2025); the current reading is higher than 50% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | 568.69% |
| FY2024 | 0.3× | (86.38%) |
| FY2023 | 2.4× | — |
| FY2022 | −0.3× | — |
| FY2021 | 2.2× | (30.78%) |
| FY2020 | 3.2× | (9.11%) |
| FY2019 | 3.5× | (31.00%) |
| FY2018 | 5.1× | 0.00% |
| FY2017 | 5.1× | 0.00% |
| FY2016 | 5.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.9× | 13.00% |
| Mar 2026 | 3.5× | 59.81% |
| Dec 2025 | 2.2× | (52.56%) |
| Sep 2025 | 4.6× | 266.27% |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TCMD Tactile Systems Technology, Inc. compare | 1.3× |
| CERS Cerus Corporation compare | 1.8× |
| BWAY Brainsway Ltd. Sponsored ADR | 2.6× |
| NPCE NeuroPace, Inc. compare | 4.2× |
| DCTH Delcath Systems, Inc. compare | 4.3× |
| SGHT Sight Sciences, Inc. compare | 4.9× |
| MASS 908 Devices Inc. compare | 5.6× |
| SENS Senseonics Holdings, Inc. compare | 8.1× |
| SSII SS Innovations International, Inc. compare | 9.6× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)